AstraZeneca's Drug Fasenra Flops in COPD Trial AstraZeneca's Drug Fasenra Flops in COPD Trial

AstraZeneca's said its first respiratory biologic medicine Fasenra (benralizumab) failed to meet its target in a clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Related Links:

This study was the largest, longest study to use a less-invasive or minimally-invasive technique using these one-way valves,” Dr. Criner said. Dr. Criner said that after one year, patients treated with the Zephyr valves were significnatly more likely to show improvements in lung function, measured as forced expiratory volume in one second, or FEV1. “Patients that were treated had about a three times greater likelihood of having significant improvement in FEV1, more than 15% in 45% of the treated group compared to 11% of the control,” Dr. Criner said. Additionally, patients treated with the Zephyr reported...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Respiratory Pulmonx Source Type: news
(MedPage Today) -- Cardiovascular outcomes similar to placebo-treated patients
Source: MedPage Today Allergy - Category: Allergy & Immunology Source Type: news
(MedPage Today) -- Cardiovascular outcomes similar to placebo-treated patients
Source: MedPage Today Pulmonary - Category: Respiratory Medicine Source Type: news
(MedPage Today) -- Oral extract of speedwell plant deemed safe in phase IIa trial
Source: MedPage Today Allergy - Category: Allergy & Immunology Source Type: news
(MedPage Today) -- Retrospective results shouldn't change practice, but deserve more study
Source: MedPage Today Allergy - Category: Allergy & Immunology Source Type: news
Conditions:   Pulmonary Disease, Chronic Obstructive;   Osteoporosis Interventions:   Diagnostic Test: Vital signs;   Diagnostic Test: Urine Pregnancy Test;   Other: Questionnaires;   Diagnostic Test: Blood Test;   Diagnostic Test: Duel-energy X-ray absorptiometry scan;   Diagnostic Test: Chest Multi-detector computed tomography Sponsors:   Punam Saha;   National Institutes of Health (NIH) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Copd Intervention:   Diagnostic Test: FEV6 spirometry Sponsor:   Cliniques universitaires Saint-Luc- Université Catholique de Louvain Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In what ways might interferon lambdas impact exacerbations and outcomes in COPD?BMC Pulmonary Medicine
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news
The Clinical Respiratory Journal, EarlyView.
Source: The Clinical Respiratory Journal - Category: Respiratory Medicine Authors: Source Type: research
Conclusion Correlations between airway parameters and lung function tests vary widely between lobes, bronchus generations and breathing states. Our work suggests that the third generation bronchus of the upper left lobe in expiration could be the preferred localization for airway quantification in future studies.
Source: European Journal of Radiology - Category: Radiology Source Type: research
More News: AstraZeneca | Chronic Obstructive Pulmonary | Clinical Trials | Health | Respiratory Medicine